Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XNW7201 in advanced solid tumors
NCT03901950Phase 1Completed
- Sponsor
- Evopoint Biosciences
- Start
- Jul 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of XNW7201 in solid tumor (advanced stage), sponsored by Evopoint Biosciences. Primary endpoints: Safety and tolerability of XNW7201 tablets up to 6 months and Dose-limiting toxicity. Started Jul 2019; status: completed.
02
Drugs
XNW7201
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03901950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03901950.